| Date | 28 January 2021 – present |
|---|---|
| Location | Morocco, Vaccination clinics |
| Cause | COVID-19 pandemic |
| Target | Immunization against COVID-19 |
| Organised by | Ministry of Health (Morocco) |
| Participants | 45,249,522 total doses administered [1] [lower-alpha 1] |
| Outcome | 62.43% of the Moroccan population has received at least one dose of a vaccine 56.84% has been fully vaccinated |
The COVID-19 vaccination in Morocco is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
The Ministry of Health has approved the following COVID-19 vaccines: Oxford–AstraZeneca, Sputnik V, and Sinopharm BIBP.
On 28 January 2021, Morocco launched a coronavirus vaccination campaign, a week after receiving its first shipment of the Oxford–AstraZeneca and Sinopharm BIBP vaccines. [2]
The government has secured 66 million doses from different manufacturers such as AstraZeneca and Sinopharm. [2]
In July 2021, it was announced that the Moroccan pharmaceutical firm Sothema would start to locally produce 5 million doses of the Sinopharm BIBP vaccine per month. [3] [4]
In January, Morocco approved the following vaccines: Sputnik V, Sinopharm BIBP, and Oxford–AstraZeneca. [5]
On 22 January, the first batch of the Oxford–AstraZeneca vaccine, consisting of 2,000,000 doses, arrived in Morocco. [6]
On 27 January, the first batch of the Sinopharm BIBP vaccine, consisting of 500,000 doses, arrived in Morocco. [7]
On 11 & 16 February, the second batches of the Oxford–AstraZeneca and Sinopharm BIBP vaccines, consisting of 4,500,000 doses, arrived in Morocco. [8] [9]
By the end of the month, 3.6 million vaccine doses had been administered.
By the end of March, 7.6 million vaccine doses had been administered while 22% of the target population had been fully vaccinated.
On 8 April, a batch of the Oxford–AstraZeneca vaccine, approximately 307,200 doses, arrived in Morocco from COVAX facility. [10]
On 26 & 30 April, two batches of the Sinopharm BIBP vaccine, consisting of 1,000,000 doses, arrived in Morocco. [11]
By the end of the month, 9 million vaccine doses had been administered while 28% of the target population had been fully vaccinated.
On 15–16 May, a batch of the Oxford–AstraZeneca vaccine, approximately 650,000 doses, arrived in Morocco. [11]
On 19 & 23 May, two batches of the Sinopharm BIBP vaccine, consisting of 4,000,000 doses, arrived in Morocco. [11]
By the end of the month, 14 million vaccine doses had been administered while 35% of the target population had been fully vaccinated.[ citation needed ]
In the first five months of the vaccination campaign, almost 10 million people received their first inoculation and 9.1 million were fully vaccinated. [12]
By the end of the month, 19 million vaccine doses had been administered while 59% of the target population had been fully vaccinated.
On 13 & 17 July, two batches of 2,000,000 doses of the Sinopharm BIBP vaccine arrived in Morocco. [13] [14]
By the end of the month, 24 million vaccine doses had been administered while 68% of the target population had been fully vaccinated.
By the end of August, 33 million vaccine doses had been administered while 88% of the target population had been fully vaccinated.
By the end of September, 41 million vaccine doses had been administered and 19 million persons were fully vaccinated. The entire targeted population had been fully vaccinated by mid-September.
By the end of October, 46 million vaccine doses had been administered and 22 million persons were fully vaccinated, exceeding the targeted population.[ citation needed ]
By the end of November, 47 million vaccine doses had been administered and 23 million persons were fully vaccinated, exceeding the targeted population.
By the end of December, 50 million vaccine doses had been administered and 23 million persons were fully vaccinated, exceeding the targeted population.
By the end of January, 52 million vaccine doses had been administered and 23 million persons were fully vaccinated, exceeding the targeted population.
By the end of February, 54 million vaccine doses had been administered and 23 million persons were fully vaccinated, exceeding the targeted population.
By the end of March, 54 million vaccine doses had been administered and 23 million persons were fully vaccinated, exceeding the targeted population.
By the end of April, 54 million vaccine doses had been administered and 23 million persons were fully vaccinated, exceeding the targeted population.
Morocco has received 7 million doses of the Oxford–AstraZeneca COVID-19 vaccine and 16.5 million doses of the Sinopharm BIBP vaccine.
| Vaccine | Approval | Deployment | Doses ordered | |
|---|---|---|---|---|
| Sinopharm BIBP |  Yes | 28 January 2021 | 45 million | |
| Oxford–AstraZeneca | 6 January 2021 | 28 January 2021 | 20 million | |
| Sputnik V | 10 March 2021 |  No | – |
| Vaccine | Type (technology) | Phase I | Phase II | Phase III |
|---|---|---|---|---|
| Sinopharm WIBP | Inactivated | Completed | Completed | Completed |
Cumulative vaccinations in Morocco [15]
 | Graphs are unavailable due to technical issues. There is more info on Phabricator and on MediaWiki.org. |
The vaccination campaign primarily targets health workers, security forces and people over 75, according to Moroccan authorities. [2]
The Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV, the Sinopharm COVID-19 vaccine, or BIBP vaccine, is one of two whole inactivated virus COVID-19 vaccines developed by Sinopharm's Beijing Institute of Biological Products. It completed Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants. BBIBP-CorV shares similar technology with CoronaVac and Covaxin, other inactivated virus vaccines for COVID-19. Its product name is SARS-CoV-2 Vaccine, not to be confused with the similar product name of CoronaVac.
The COVID-19 vaccination program in the Philippines was a mass immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the pandemic in the country. The vaccination program was initiated by the Duterte administration on March 1, 2021, a day after the arrival of the country's first vaccine doses which were donated by the Chinese government.
On 29 January 2021, Algeria launched a COVID-19 vaccination campaign, a day after receiving its first shipment of 50,000 doses of the Russia's Sputnik V vaccine. As of 6 June 2021, around 2.5 million doses have been administered. Algeria is currently vaccinating its population with both Sputnik V and Oxford-AstraZeneca vaccines.
COVID-19 vaccination in Angola is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country. As of 15 June 2021, Angola has administered 1,314,375 doses of vaccines.822,109 people with the first dose and 492,266 people fully vaccinated. Angola began their vaccination program shortly after receiving their first shipment of Oxford AstraZeneca vaccine in early March 2021.
COVID-19 vaccination in Botswana is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
Cape Verde has begun vaccinations against COVID-19.
On 23 February 2021, Senegal began its national vaccination program against the COVID-19. As of 10 March, 68,205 people in Senegal have been able to be vaccinated.
COVID-19 vaccination programs are ongoing in the majority countries and territories in Africa, with 51 of 54 African countries having launched vaccination programs by July 2021. As of October 2023, 51.8% of the continent's population is fully vaccinated with over 1084.5 million doses administered.
COVID-19 vaccination in Ghana began on Monday 1 March 2021 after the country became the first recipient of the Oxford-AstraZeneca COVID-19 vaccine as part of the COVAX initiative. As of 6 June 2021, Ghana has administered 1,230,000 vaccine doses.
Bhutan has promised a free COVID-19 vaccination to all of its citizens, both inside and outside the country. It started mass vaccinations on 27 March 2021.
The COVID-19 vaccination in Vietnam is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in response to the ongoing pandemic in the country. Following the approval of the Oxford–AstraZeneca COVID-19 vaccine on 30 January 2021, vaccinations commenced on 8 March 2021, and will continue throughout the year with the goal of vaccinating 80% of the population by June 2022. The Sputnik V was later approved for use on 23 March 2021. The Sinopharm BIBP vaccine was approved for emergency use on 4 June 2021, while Pfizer–BioNTech COVID-19 vaccine, Moderna COVID-19 vaccine and Janssen COVID-19 vaccine were approved on 12 June 2021, 29 June 2021, and 15 July 2021, respectively. Vietnam approved Abdala vaccine from Center for Genetic Engineering and Biotechnology on 18 September 2021, and Covaxin from Bharat Biotech on 10 November 2021.
The COVID-19 vaccination in Indonesia is an ongoing mass immunization in response to the COVID-19 pandemic in Indonesia. On 13 January 2021, the program commenced when President Joko Widodo was vaccinated at the presidential palace. In terms of total doses given, Indonesia ranks third in Asia and fifth in the world.
COVID-19 vaccination in Nigeria is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country. Vaccination began on 5 March 2021. As of 28 February 2022, 17,914,944 people have received their first dose a COVID-19 vaccine, and 8,197,832 have received their second dose.
Bangladesh began the administration of COVID-19 vaccines on 27 January 2021 while mass vaccination started on 7 February 2021.
COVID-19 vaccination in Sri Lanka is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, in response to the ongoing pandemic in the country. As of late July, the Sinopharm BIBP vaccine accounted for 78% of the total 13.8 million vaccines obtained by Sri Lanka to date. The United States donated over 1.5 million Moderna vaccine through COVAX.
COVID-19 vaccination in Burundi is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country. Burundi was one of the last nation states in the world to commence vaccination against COVID-19. This was mostly due to the government's refusal to vaccinate the population throughout most of 2021. In February 2021, Thaddee Ndikumana, the health minister of Burundi, said his country was more concerned with prevention measures. "Since more than 95% of patients are recovering, we estimate that the vaccines are not yet necessary," local media reported.
COVID-19 vaccination in Chad is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
COVID-19 vaccination in Egypt is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
COVID-19 vaccination in Equatorial Guinea is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
COVID-19 vaccination in Eswatini is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.